(HealthDay News) — In a research letter published online in Circulation, seven cases are presented of patients hospitalized for acute myocarditis-like illness following COVID-19 vaccination.

Carolyn M. Rosner, from the Inova Heart and Vascular Institute in Fairfax, Virginia, and colleagues offer details on a total of 7 patients hospitalized at 2 US medical centers for acute myocarditis-like illness following COVID-19 vaccination.

The researchers note that all seven patients were male, younger than 40 years of age, and of White or Hispanic race/ethnicity. One of the patients reported a previous COVID-19 infection. Six of the patients had received an mRNA vaccine, and 1 patient had received the adenovirus vector vaccine. All patients presented at 3 to 7 days after vaccination with acute onset of chest pain and biochemical evidence of myocardial injury (cardiac troponin I or elevated high-sensitivity troponin I). None of the patients had a pericardial friction rub or rash; all were hemodynamically stable. There was variation noted in the electrocardiogram patterns, from normal to ST segment elevation. Left ventricular ejection fraction varied from 35 to 62%, with 5 patients having some degree of hypokinesis. No patient had evidence of an active viral illness or autoimmune disease. Treatment included a beta-blocker and anti-inflammatory medication. Hospital length of stay was 3 ± 1 days, and by hospital discharge, all patients’ symptoms were resolved.

Continue Reading

“The clinical course of vaccine-associated myocarditis-like illness appears favorable, with resolution of symptoms in all patients,” the authors write. “Given the potential morbidity of COVID-19 infection even in younger adults, the risk-benefit decision for vaccination remains highly favorable.”

Several authors disclosed financial ties to the medical diagnostics industry.

Abstract/Full Text